Literature DB >> 7637095

Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells.

D R Harriss1, K A Marsh, A T Birmingham, S J Hill.   

Abstract

PURPOSE: To investigate the effect of muscarinic receptor agonists and antagonists on the accumulation of inositol phosphates in cultures of human detrusor smooth muscle cells.
MATERIALS AND METHODS: Primary explant culture was used to derive smooth muscle cell lines from small bladder biopsies. The cells were loaded with [3H]-myoinositol, stimulated with muscarinic agonists, and the accumulation of [3H]-inositol phosphates was measured by liquid scintillation counting.
RESULTS: Carbachol (EC50 8.3 microM.), methacholine (EC50 7.5 microM.), oxotremorine (EC50 2.5 microM.) and pilocarpine (EC50 8.3 microM.) produced concentration-dependent rises in the accumulation of total [3H]-inositol phosphates. M1 (pirenzepine), M2 (methoctramine) and M3 (4-DAMP and pf-HHSiD) muscarinic receptor antagonists significantly antagonized the response induced by a submaximal concentration of carbachol (100 microM.). The apparent pA2 values were atropine (9.4), 4-DAMP (9.2), pfHHSid (7.4), pirenzepine (6.9) and methoctramine (6.3).
CONCLUSIONS: These results indicate that human detrusor smooth muscle cells in culture express M3 muscarinic receptors which are linked to phosphoinositide hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637095

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Does ivabradine exhibit a role in the reduction of bladder overactivity?

Authors:  K Stamatiou; I Heretis; E Skoumbourdis
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 2.  [Not Available].

Authors:  Abdelmounaim Qarro; Mohammed Asseban; Khalil Bazine; Mohammed Najoui; Jamaleddine Samir; Youssef Ouhbi; Amoqrane Beddouch; Mohammed Lezrek; Mohammed Alami
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

3.  The intracellular pathway of the acetylcholine-induced contraction in cat detrusor muscle cells.

Authors:  J Y An; H S Yun; Y P Lee; S J Yang; J O Shim; J H Jeong; C Y Shin; J H Kim; D S Kim; U D Sohn
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder.

Authors:  A S Braverman; G R Luthin; M R Ruggieri
Journal:  Am J Physiol       Date:  1998-11

5.  In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.

Authors:  C Salcedo; S Davalillo; J Cabellos; C Lagunas; D Balsa; S Pérez-Del-Pulgar; M Ballarín; Ag Fernández
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

Review 6.  Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Authors:  Kyu-Sung Lee; Hye Won Lee; Deok Hyun Han
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

7.  The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction.

Authors:  Michel A Pontari; Alan S Braverman; Michael R Ruggieri
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-01-29       Impact factor: 3.619

8.  BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels.

Authors:  Serge A Y Afeli; Eric S Rovner; Georgi V Petkov
Journal:  Urology       Date:  2013-07-26       Impact factor: 2.649

Review 9.  Muscarinic receptors in the bladder: from basic research to therapeutics.

Authors:  Sharath S Hegde
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 10.  Treatment of overactive bladder in the aging population: focus on darifenacin.

Authors:  Swati Jha; Matthew Parsons
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.